View Post

Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab

In Clinical Trials by Barbara Jacoby

Source: Checkpoint Therapeutics, Inc From: apnews.com >40% objective response rates observed in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma Well-tolerated safety profile Enrollment ongoing in expansion cohorts intended to support potential BLA submissions Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with …

View Post

Immunotherapy for lung cancer: Researchers working to broaden its reach

In Clinical Trials by Barbara Jacoby

By: Scott Merville From: mdanderson.org Immunotherapy drugs have produced promising results in cancers like melanoma and leukemia, yet the drugs only work for 20 percent of lung cancer patients. MD Anderson researchers are working to change that. Immunotherapy drugs that free the immune system to attack cancer have provided durable responses for about 20 percent of lung cancer patients, which …

View Post

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin® Trial in Breast Cancer-Associated Lymphedema

In Clinical Trials by Barbara Jacoby

Source: Herantis Pharma Oyj From: globenewswire.com Herantis Pharma Plc (“Herantis”) announced today the topline results from the 12-month follow-up review of the Phase 1 Lymfactin® trial in breast cancer-associated lymphedema. The study’s data monitoring committee (DMC) concluded that the treatment continues to be safe and well-tolerated in all patients with no severe adverse events. Lymfactin®, the novel gene therapy of …

View Post

Cyclacel Pharma (CYCC) Presents Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

In Clinical Trials by Barbara Jacoby

From: streetinsider.com Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced Phase 1 clinical data from the company’s DNA damage response program with an oral, sequential regimen of sapacitabine and seliciclib as a treatment in patients with BRCA mutant metastatic breast cancer. Data from the study was presented today at the 2019 American Association for Cancer Research (AACR) Annual Meeting and demonstrated that …

View Post

Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity

In Clinical Trials by Barbara Jacoby

Provider: Business Wire From: apnews.com Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled “ Safety and Immunogenicity of a Personalized Neoantigen-Listeria Vaccine in Cancer Patients” at the American Association for Cancer Research (AACR) Annual Meeting underway in Atlanta. The discussion …

View Post

Findings About Children’s Solid Tumors Are Sparking New Therapies

In Clinical Trials by Barbara Jacoby

By: Beth Fand Incollingo From: curetoday.com Compared with solid tumors in adults — about which scientists are learning more and more — those that occur in children are mysteries. Not only are pediatric tumors rare, but they arise in developing tissues, making them difficult to study and treat. That’s where the Childhood Solid Tumor Network (CSTN), run by St. Jude …

View Post

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

In Clinical Trials by Barbara Jacoby

Source: Sorrento Therapeutics, Inc. From: apnews.com Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. This Phase 1 dose-escalation study, approved by the South Korean Ministry …

View Post

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

In Clinical Trials by Barbara Jacoby

Source: NKMax America, Inc. From: prnewswire.com NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for SNK01, an autologous NK cell adoptive immunotherapy candidate for the treatment of patients …

View Post

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

In Clinical Trials by Barbara Jacoby

From: mesothelioma.net An exciting new immunotherapy treatment is now being tested in a phase I clinical trial that is still recruiting for participants. This provides a unique opportunity for patients who qualify to get access to an innovative medicine with great promise. Known as CAR T-cell therapy, this new treatment uses gene therapy to modify a patient’s immune system cells. …

View Post

Servier, in Collaboration with Allogene Therapeutics, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy

In Clinical Trials by Barbara Jacoby

Source: Allogene Therapeutics Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma ALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion Regimen Paris (France) and South San Francisco, Calif. – January 28, 2019 – Servier, an independent international pharmaceutical company and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical- stage biotechnology company pioneering the …